Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $34.00

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $34.00.

Several brokerages have recently commented on ARCT. Guggenheim lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. BTIG Research reduced their price objective on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Wells Fargo & Company reduced their target price on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, October 23rd. HC Wainwright decreased their price target on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Finally, Zacks Research cut Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. boosted its holdings in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA bought a new stake in Arcturus Therapeutics in the 3rd quarter valued at $111,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,567 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Arcturus Therapeutics by 42.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 2,313 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

NASDAQ:ARCT opened at $7.37 on Thursday. The stock has a market cap of $209.38 million, a PE ratio of -3.00 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17. The stock’s 50-day moving average is $6.94 and its two-hundred day moving average is $12.33.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.60. Arcturus Therapeutics had a negative return on equity of 28.68% and a negative net margin of 68.35%.The firm had revenue of $17.15 million for the quarter, compared to the consensus estimate of $17.47 million. On average, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.